9-6-2017

The biogenesis pathway of tRNA-derived piRNAs in Bombyx germ cells.

Shozo Honda  
*Thomas Jefferson University, Shozo.Honda@jefferson.edu*

Takuya Kawamura  
*Thomas Jefferson University, Takuya.Kawamura@jefferson.edu*

Phillipe Loher  
*Thomas Jefferson University, Phillipe.Loher@jefferson.edu*

Keisuke Morichika  
*Thomas Jefferson University*

Isidore Rigoutsos  
*Thomas Jefferson University, Isidore.Rigoutsos@jefferson.edu*

*See next page for additional authors*

Let us know how access to this document benefits you

Follow this and additional works at: [https://jdc.jefferson.edu/tjucompmedctrfp](https://jdc.jefferson.edu/tjucompmedctrfp)

Part of the [Medicine and Health Sciences Commons](https://jdc.jefferson.edu/tjucompmedctrfp)

**Recommended Citation**

Honda, Shozo; Kawamura, Takuya; Loher, Phillipe; Morichika, Keisuke; Rigoutsos, Isidore; and Kirino, PhD, Yohei, "The biogenesis pathway of tRNA-derived piRNAs in Bombyx germ cells." (2017). *Computational Medicine Center Faculty Papers*. Paper 21.  
[https://jdc.jefferson.edu/tjucompmedctrfp/21](https://jdc.jefferson.edu/tjucompmedctrfp/21)
The biogenesis pathway of tRNA-derived piRNAs in *Bombyx* germ cells

Shozo Honda, Takuya Kawamura, Phillipe Loher, Keisuke Morichika, Isidore Rigoutsos and Yohei Kirino∗

Computational Medicine Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA

Received March 16, 2017; Revised June 08, 2017; Editorial Decision June 09, 2017; Accepted June 20, 2017

**ABSTRACT**

Transfer RNAs (tRNAs) function in translational machinery and further serve as a source of short non-coding RNAs (ncRNAs). tRNA-derived ncRNAs show differential expression profiles and play roles in many biological processes beyond translation. Molecular mechanisms that shape and regulate their expression profiles are largely unknown. Here, we report the mechanism of biogenesis for tRNA-derived Piwi-interacting RNAs (td-piRNAs) expressed in *Bombyx* BmN4 cells. In the cells, two cytoplasmic tRNA species, tRNAAspGUC and tRNAHisGUG, served as major sources for td-piRNAs, which were derived from the 5′-part of the respective tRNAs. cP-RNA-seq identified the two tRNAs as major substrates for the 5′-tRNA halves as well, suggesting a previously uncharacterized link between 5′-tRNA halves and td-piRNAs. An increase in levels of the 5′-tRNA halves, induced by BmNSun2 knockdown, enhanced the td-piRNA expression levels without quantitative change in mature tRNAs, indicating that 5′-tRNA halves, not mature tRNAs, are the direct precursors for td-piRNAs. For the generation of tRNAHisGUG-derived piRNAs, BmThg1l-mediated nucleotide addition to −1 position of tRNAHisGUG was required, revealing an important function of BmThg1l in piRNA biogenesis. Our study advances the understanding of biogenesis mechanisms and the genesis of specific expression profiles for tRNA-derived ncRNAs.

**INTRODUCTION**

Transfer RNAs (tRNAs) are ~70–90-nucleotides (nt) of non-coding RNAs (ncRNAs) that are universally expressed in all organisms and function as fundamental adapter components of translational machinery to translate mRNA codons into amino acids of proteins (1,2). Besides their role in translation, tRNAs further serve as substrates for shorter ncRNAs. In many organisms, specific ncRNAs are produced from mature tRNAs or their precursor molecules (pre-tRNAs) to serve as functional molecules, rather than random degradation products (3–8). In general, tRNA-derived ncRNAs are classified into two groups: tRNA halves and tRNA-derived fragments (tRFs). tRNA halves range either from the 5′-end to the anticodon-loop (5′-half) or from the anticodon-loop to the 3′-end (3′-half) of a mature tRNA, and their production is triggered by stresses and sex hormone signaling pathways (6,9,10). 5′-tRNA halves have been shown to be functional molecules that regulate translation, promote stress granule formation and cell proliferation, and are involved in neurodegenerative diseases and aging (10–16). Generally shorter than tRNA halves, tRFs originate from the 5′-part (5′-tRF), 3′-part (3′-tRF) or wholly internal part (i-tRF) of mature tRNAs or other precursor sequences (3–8,17). They show differential but specific expression profiles in different cells and tissues and are involved in many biological processes, such as cell proliferation, tumor suppression and priming of viral reverse transcriptase (3–8,17). Although tRF expressions might be able to serve as indicators for biological states, it is still unknown as to how the specific expression profiles of tRFs are shaped.

The functional significance of tRFs is particularly evident by their involvement in the pathway of small regulatory RNAs bound by Argonaute family proteins (7). It has been shown that a variety of tRFs are selectively and differentially loaded onto the Ago subclade of the Argonaute family in human cells (17–24). These types of Ago-loaded tRFs are further known to function as microRNAs (miRNAs) by repressing the expression of their complementary target mRNAs. For example, Ago-bound 3′-tRFlysUUU (3′-tRF derived from tRNAlysUUU) silences HIV-1 in MT4 T-cells (25), while Ago-bound 3′-tRFGlyGCC modulates DNA damage response by targeting RPA1 in human B cells (26). The presence of Ago-bound tRFs has also been reported for many other organisms, such as the mouse (27), *Drosophila* (28,29), *Bombyx* (30) and in plant (31). However, despite the widespread presence and evident functional significance of Ago-bound tRFs as miR-
NAVs, their biogenesis mechanisms remain largely elusive. Although both Dicer-dependent and independent biogenesis pathways have been suggested (18,19,21,22,26,28,32), the molecular mechanisms underlying the selection of tRNAs for miRNA biogenesis and specific and differential Ago-loading of each of the tRFs is unknown.

Piwi proteins, the other Argonaute subclade, are predominantly expressed in the germline and are associated with ~26–31 nt Piwi-interacting RNAs (piRNAs) to regulate transposons and other targets for maintaining genome integrity (33,34). Piwi proteins, like Ago proteins, have also been observed interacting with tRFs in various organisms, such as human (35), marmoset (36), Drosophila (37–39), and Trypanosoma (40). The functional significance of Piwi-bound tRFs was shown in Tetrahymena where TWI12 was tightly bound to tRFs, and played crucial roles in stimulating Xrn2 exonuclease for nuclear RNA processing (41,42). However, as in the case of Ago-loaded tRFs, the biogenesis mechanisms producing Piwi-bound tRFs remain unknown. Only specific species of tRFs are selectively loaded onto Piwi proteins as piRNAs. For example, 5′-tRFGluCUC is predominantly loaded onto the Piwi protein in marmoset testes (36), while 5′-tRFGluCUC and t-RF-GluCUC are abundant as Piwi-bound tRFs in Drosophila Kc167 cells (39). The molecular mechanisms underlying the selection of tRNAs for piRNA biogenesis and specific Piwi-loading of different tRF species in different organisms are completely unknown.

To unravel the emerging complexities of tRF biology, it is imperative to understand the tRF biogenesis mechanism that induces specific expression profiles of tRFs. Here we report the characterization of the expression profile and biogenesis mechanism of tRNA-derived piRNAs (t-dpiRNAs) by utilizing BmN4 cells, a culturable germ cell line derived from Bombyx mori ovary. BmN4 cells possess fully functional primary and secondary piRNA biogenesis pathways, and express both Bombyx Piwi proteins, Siwi and BmAgo3, as well as their bound piRNAs (43). Because of the scarcity of piRNA-expressing culturable germ cell line, BmN4 cells have been used often to elucidate the cause of the scarcity of piRNA-expressing culturable germ cell line derived from Drosophila where TWI12 was characterized to induce specific expression profiles of tRNAs for piRNA biogenesis and specific Piwi-loading of different tRF species in different organisms are completely unknown.

Quantification of 5′-tRNA halves and td-piRNAs by TaqMan qRT-PCR
TaqMan qRT-PCR quantification of 5′-tRNA halves and td-piRNAs was performed according to our previously described tRNA halves’ quantification method (10) with modifications (Supplementary Figure S1). Total RNA was at first incubated with 10 mM NaIO4 at 0°C for 40 min in the dark to disrupt 3′-OH ends of tRNAs. 5′-tRNA halves and piRNAs survive the treatment because of the presence of a 2′,3′-cyclic phosphate (cP) and 2′-O-methyl modification at the 3′-end, respectively. For quantification of 5′-tRNA halves (5′-halfAspGUC and 5′-halfAspGUCU), total RNA was then treated with T4 PNK to dephosphorylate the 3′-end of 5′-tRNA halves. For quantification of td-piRNAs (td-piRAspGUC and td-piRAspGUCU), the NaIO4-treated RNA was subjected to the next step without any pretreatment. For both cases, 10 ng of the treated RNAs were subjected to a ligation reaction (10-μL reaction mixture) with 20 pmol of a 3′-RNA adaptor (5′-P-GAACACUGCUUGAGCGCUUUUG AGAGUUCUACAGUCGGAGCGAUC-ddC-3′) using T4 RNA Ligase (T4 Rnl; Fisher Scientific). Subsequently, 1 ng of ligated RNA was subjected to TaqMan qRT-PCR (10-μL reaction mixture) using the One Step PrimeScript RT-PCR Kit (Clontech), 400 nM of a TaqMan probe targeting the boundary of the targeted RNA and 3′-RNA adaptor, and 2 pmol each of specific forward and reverse primers. With the StepOne Plus Real-time PCR machine (Life Technologies), the reaction mixture was incubated at 42°C for 5 min and then 95°C for 10 s, followed by 40 cycles of 95°C for 5 s and 60°C for 34 s. The quantified RNA levels were normalized to the levels of Bombyx 5S rRNA quantified by qRT-PCR using a stem-loop reverse primer (see below sec-
tion). The sequences of the primers and TaqMan probes are shown in Supplementary Table S1.

Northern blot

Northern blot analysis was performed as described previously (44). Briefly, 5 μg of total RNA were resolved by 12% PAGE containing 7 M urea using the SE400 Electrophoresis Unit (Hoefer) or sequencing system aluminum 2 (Thermo Fisher Scientific), transferred to Hybond N+ membranes (GE Healthcare), and hybridized to 5′-end-labeled antisense probes whose sequences are shown in Supplementary Table S2.

cP-RNA-seq to selectively amplify and sequence 5′-tRNA halves

cP-RNA-seq was performed as described previously (10,49). Briefly, ∼30–40-nt RNAs were gel-purified from BmN4 total RNA and treated with CIP. After phenol-chloroform purification, the RNAs were oxidized by incubation in 10 mM NaIO4 at 0°C for 40 min in the dark, followed by ethanol precipitation. The RNAs were then treated with T4 PNK. After phenol-chloroform purification, directional ligation of adapters, cDNA generation, and PCR amplification were performed using the TruSeq Small RNA Sample Prep kit (Illumina) according to the manufacturer’s protocol. The amplified cDNAs were sequenced using Illumina hiSeq2000 system at the Functional Genomics Core at the University of Pennsylvania.

Bioinformatics analyses

To identify td-piRNA sequences expressed in BmN4 cells, Bombyx tRNA reference sequences were extracted by applying tRNA scan program (50) for Bombyx mori genome (http://www.silkdb.org/silkdb/). Variant sequences of Bombyx cytoplasmic (cyto) tRNAAspGUC, tRNAHisGUG tRNAHisGUC, and tRNAHisGUC are shown in Supplementary Figure S2. The six piRNA libraries [1: Siwi-piRNAs; 2: BmAgo3-piRNAs; 3: Siwi-piRNAs from Rluc (control) depleted cells; 4: Siwi-piRNAs from BmPapi-depleted cells; 5: BmAgo3-piRNAs from Rluc-depleted cells; 6: BmAgo3-piRNAs from BmPapi-depleted cells; DDBJ #DRA002562], obtained from Siwi- or BmAgo3-immunoprecipitates of BmN4 cells in our previous study (44), were then mapped to the tRNA reference sequences using SHRIMP2 (51), which allowed a 4% mismatch rate for human THG1L (NP_060342.2) and NSUN2 (NP_060225.4) using tblastn algorithm; these genes were named as BmThgil and BmNSun2, respectively (Supplementary Figures S3 and S4). RNAi knockdowns of BmThgil and BmNSun2 in BmN4 cells was performed as described previously (44) with minor modifications. Briefly, to synthesize templates for the in vitro production of dsRNA, BmN4 total RNA was extracted using RNeasy mini kit (Qiagen), and reverse transcription was performed with random hexamer primers. The resultant cDNAs were used as templates for PCR with specific forward and reverse primers shown in Supplementary Table S3. The amplified DNAs containing T7 promoter sequence on both strands were used as templates in a T7 in vitro transcription system (MEGAscript T7, Ambion), followed by purification with MEGAclear (Ambion). The synthesized and purified dsRNA (6 μg) was transfected into 3 × 106 BmN4 cells using 4D-Nucleofector (Lonza). After culturing for 5 days, an identical dsRNA transfection was performed again. After culturing for another 2 days, to accelerate de novo synthesis of piRNAs, 6 μg of a pIZ-based plasmid encoding FLAG-tagged Siwi or BmAgo3 (44) were transfected using 30 μl of Escort IV Transfection Reagent (Sigma) into BmThgil- or BmNSun2-depleted cells, respectively. After culturing for another 2 days, the cells were harvested for the analyses of piRNAs, tRNAs, tRNA halves and mRNAs. To confirm the efficiency of the RNAi knockdowns, the expression levels of targeted mRNAs were analyzed by qRT-PCR using 2 × qPCR Master Mix (Bioland Scientific LLC) and the primers shown in Supplementary Table S4. BmRp49 was used as a control for normalization.

qRT-PCR using a stem-loop reverse primer

Two piRNAs (piR-1 and piR-2) and let-7 miRNA were quantified by qRT-PCR using a stem-loop reverse primer that is based on miRNA quantification by stem-loop qRT-PCR (52). By using StepOne Plus Real-time PCR machine (Life Technologies), the reaction mixture consisted of One-Step SYBR PrimeScript® RT-PCR Kit II (Clontech) and the primers shown in Supplementary Table S5 was incubated at 16°C for 15 min, 42°C for 15 min, and then 95°C for 10 s, followed by 40 cycles of 95°C for 5 s and 60°C for 34 s. 5S rRNA was used as a control for normalization.

RESULTS

Cytoplasmic tRNAAspGUC and tRNAHisGUG are rich sources of piRNAs in BmN4 cells

Our previous analyses, using BmN4 cells, detected the expression of piR-a, which is derived from the 5′-part of Bombyx cytoplasmic (cyto) tRNAAspGUC (10). The piR-a is a
Figure 1. Identification of td-piRNAs in BmN4 cells. (A) BmN4 Siwi- or BmAgo3-bound piRNAs were mapped against *Bombyx mori* tRNA sequences. Among the tRNA-mapped piRNA reads, pie charts show the percentages of the reads derived from respective cyto tRNA species. (B) The 5'-terminal position of Siwi- or BmAgo3-bound td-piR*AspGUC* or td-piR*HisGUG* in the respective mature tRNA. Nucleotide positions (np) are indicated according to the nucleotide numbering system of tRNAs (2). (C) The regions from which td-piR*AspGUC* starting from np 1, or td-piR*HisGUG*, starting from np –1, were derived are shown in black in the cloverleaf secondary structure of *Bombyx* cyto tRNA*AspGUC*V1 (Supplementary Figure S2) and tRNA*HisGUG*. Non-piRNA-derived regions are shown in gray. (D) Read-length distribution of the Siwi- or BmAgo3-bound total piRNAs, td-piR*AspGUC*, or td-piR*HisGUG* identified in Rluc-depleted (control) or BmPapi-depleted BmN4 cells.
5′-tRFAspGUC sharing an identical 5′-end with the mature tRNA and corresponding to the nucleotide position (np) 1–28 (np is according to the nucleotide numbering system of tRNAs (2)). Because piR-a was among the most abundant piRNA species detected in our previous piRNA sequencing (44), we hypothesized that tRNAs are rich sources of piRNAs in BmN4 cells. To explore the td-piRNA species, we mapped Siwi- or BmAgo3-bound piRNA sequences, previously identified by Illumina sequencing of the RNAs from Siwi- or BmAgo3-immunoprecipitates (44), to Bombyx tRNA sequences. Among the tRNA-mapped reads, we focused on RNA species with >1 reads per million (rpm). Among the total 52 species of Bombyx cyto tRNA isoacceptors, only a few cyto tRNA species were found to be major sources of Siwi- or BmAgo3-bound td-piRNAs (Figure 1A). The two species, cyto tRNAAspGUC and tRNAHisGUG, were particularly enriched as td-piRNA sources, comprising 86.9% or 97.1% of the total Siwi- or BmAgo3-bound td-piRNAs, respectively. Most td-piRAspGUC were derived from np 1–25–29 of mature tRNAAspGUC (Figure 1B and C). As mature tRNAHisGUG is known to contain one extra evolutionally-conserved 5′-terminal nucleotide at np –1 (2,53), td-piRHisGUG was derived mainly from np –1–23–29 of mature tRNA (Figure 1B and C). Therefore, both td-piRNAs belong to 5′-tRF with an identical 5′-terminal position to mature tRNAs and with variations at their 3′-terminal positions. Cyto tRNAAspGUC and/or tRNAHisGUG were also found to be a source (6.5%) for Siwi-bound td-piRNAs (Figure 1A), and td-piRAspGUC/CUC belongs to 5′-tRF as well (Supplementary Figure S5A and B). Although only 1% of the Siwi- or BmAgo3-bound piRNAs are annotated to Bombyx tRNAs (44), the enrichment of td-piRNAs for only specific species make those among the most abundant piRNAs; the most abundant td-piRNAs, tRNAAspGUC (np 1–28) in Siwi-bound piRNAs and tRNAHisGUG (np –1–25) in BmAgo3-bound piRNAs, rank among the top 20 of all identified individual piRNA species. Therefore, cyto tRNAAspGUC and tRNAHisGUG are very rich sources of piRNAs expressed in BmN4 cells.

In BmN4 cells, overall lengths of Siwi-bound piRNAs are longer than BmAgo3-bound piRNAs (44). This tendency is retained for both td-piRAspGUC and td-piRHisGUG (Figure 1D), suggesting that the two td-piRNAs are produced from a canonical piRNA biogenesis mechanism. To further address this point, we analyzed the two td-piRNAs in BmPapi-depleted BmN4 cells. BmPapi is a piRNA biogenesis factor that localizes at the outer membrane of mitochondria and supports PNLC1-catalyzed 3′-end maturation of piRNAs (44,48). Due to its role in piRNA 3′-end maturation, BmPapi depletion globally causes a 3′-terminal extension of piRNA lengths (44). As shown in Figure 1D, the lengths of both td-piRAspGUC and td-piRHisGUG in BmPapi-depleted cells were longer than those in control cells, suggesting that the two td-piRNAs are bona-fide piRNAs produced via a canonical piRNA biogenesis mechanism, including the 3′-end maturation step catalyzed by PNLC1 in support of BmPapi.

Because both td-piRAspGUC and td-piRHisGUG species share identical 5′-ends with mature tRNAs, these td-piRNAs are likely to originate from mature tRNAs resulting from the RNase P-mediated removal of 5′-leader sequences. However, mature tRNAs in the cytoplasm usually exist as aminoacylated forms that are tightly bound by an elongation factor for translation. Questions remained regarding how these tRNAs, forming rigid structures with interacting proteins, enter a piRNA biogenesis system where they are loaded onto Piwi proteins before PNLC1-mediated processing, and why only specific tRNA species (i.e. tRNAAspGUC and tRNAHisGUG) are selected for piRNA production.

**tRNA halves are produced from mature aminoacylated tRNAAspGUC and tRNAHisGUG in BmN4 cells**

In BmN4 cells, our previous study revealed abundant accumulation of tRNA halves derived from cyto tRNAAspGUC and tRNAHisGUG (10). Both the 5′- and 3′-halves of the tRNAs manifested clear signals in northern blots, but we failed to detect signals for tRNA halves from other randomly chosen tRNAs (10). Because the specific expression of tRNA halves from cyto tRNAAspGUC and tRNAHisGUG was reminiscent of the specific expression of td-piRNAs from the two tRNAs, we next analyzed the expression profiles of tRNA halves.

In human hormone-dependent cancer cells, angiogenin (ANG), a member of the RNase A superfamily, cleaves the anticodon-loop of mature tRNAs to generate: (i) 5′-halves containing a 5′-terminal phosphate (5′-P) and a 3′-terminal 2′,3′-cyclic phosphate (3′-cP) and (ii) 3′-halves containing a 5′-terminal hydroxyl group (5′-OH) and a 3′-terminal amino acid (3′-aa) (10). To analyze 3′-terminal structures of the 5′-halves derived from tRNAAspGUC and tRNAHisGUG (5′-halfAspGUC and 5′-halfHisGUG, respectively) expressed in BmN4 cells, total RNA was treated with T4 polynucleotide kinase (T4 PNK) or calf intestine phosphatase (CIP). T4 PNK removes both 3′-P and 3′-cP from RNAs, whereas CIP removes only a 3′-P and cannot remove a 3′-cP. Subsequently, efficiency of the ligation between the 5′-halves and a 3′-RNA adapter was examined by TaqMan qRT-PCR with a TaqMan probe that targets the boundary of the 5′-halves and the adapter. This was specifically for quantifying ligation products without cross-reaction from mature tRNAs or unligated tRNA halves. As shown in Figure 2A, the T4 PNK treatment, but not the CIP treatment, drastically increased the ligation efficiency of an RNA adapter to 5′-halves. No such increase was observed in control experiments for piRNAs which do not contain 3′-cP. These results suggest that 5′-halves contain a 3′-terminal cP, as shown in the 5′-halves expressed in human cancer cells.

To analyze the 3′-terminal structure of the 3′-half, BmN4 total RNA was subjected to deacylation treatment to remove amino acids from aminoacylated tRNAs. This was followed by sodium periodate oxidation and β-elimination, which reacts with the 3′-OH end to remove the 3′-terminal nucleotide (10). As shown in Figure 2B, β-eliminated 3′-halfAspGUC and 3′-halfHisGUG, as well as corresponding mature tRNAs, migrated faster than unreacted RNAs only after the RNAs were subjected to the deacylation treatment. In other words, without the deacylation treatment, β-elimination was unable to react with the 3′-end of the 3′-halves and the mature tRNAs because of the presence of an
therefore that the production of 5\'-RNA-seq despite the absence of a 3\'-terminal nucleotide at np 1, and its 5\'-half expressed in human BT-474 cells. In addition to 5\'-terminal nucleotide at np 1 (G\(_1\)) has been widely known to be conserved across phyla (2), our recent study revealed the existence of other three 5\'-terminal nucleotides (U\(_{-1}\) >> A\(_{-1}\) C\(_{-1}\)) in tRNA\(_{HisGUG}\), in addition to G\(_{-1}\), and its 5\'-half expressed in human BT-474 breast cancer cells (53). As observed in BT-474 cells, cP-RNA-seq data showed wide variations of 5\'-terminal nucleotides from 5\'-halfHisGUG in BmN4 cells. In addition to 5\'-halfHisGUG lacking a 1 45-bp cDNA bands (considering adapters’ lengths, inserted RNAs were estimated to be ~27 nt). However, the full cP-RNA-seq procedures amplified ~153-bp cDNA bands (inserted RNAs: ~35 nt) that were much more abundant than piRNA bands in the same lane (Figure 3A). The dependency of the bands on T4 PNK treatment suggests that, as expected, the bands were derived from cP-containing 5\'-tRNA halves.

Illumina sequencing of the ~153-bp cDNA bands yielded ~53 million reads after the quality check and adapter trimming, of which ~31 million reads (~59%) were actually mapped against *Bombyx* tRNA sequences. The tRNA-mapped reads were mostly 33 or 34 nt in length (Figure 3B), and derived from specific species of tRNAs. When we focused the tRNA-mapped reads to greater than 1 rpm with over 31-nt length that in aggregate accounted for 99.2% of the reads, only four cyto tRNA species (tRNA\(_{AspGUC}\), tRNA\(_{LysCUU}\), tRNA\(_{HisGUG}\), and tRNA\(_{AspCUU}\)) were identified to be a source of the reads with >1% of the tRNA-mapped reads, and another four cyto tRNA species (tRNA\(_{GluCUC}\), tRNA\(_{GlyGCC}\), tRNA\(_{GluCUU}\) and tRNA\(_{GluCUU}\)) corresponded to the reads with 0.2–1% of the tRNA-mapped reads (Figure 3C). Reads derived from tRNA\(_{AspGUC}\) were particularly enriched, comprising 85.1% of the total tRNA-mapped reads. Of the reads mapped to the four tRNAs, almost all sequences were uniformly derived from 5\'-halves ranging from the 5\'-end [np 1 (or np –1 for tRNA\(_{HisGUG}\)] to np 32–35 (Figure 3D). The abundant presence of 5\'-halfAspGUC and 5\'-halfHisGUG was consistent with the results from the Northern blots in our previous study (10). Further northern blots confirmed the accumulation of 5\'-halfLysCUU and 5\'-halfGluCUU/CUC, as identified by cP-RNA-seq, but not of unidentified 5\'-halves derived from randomly-chosen tRNAs, tRNA\(_{GluUUC}\), tRNA\(_{ValCGA}\) and tRNA\(_{SerCUU}\) (Supplementary Figures S5 and S6), suggesting credibility of the cP-RNA-seq results. Although we failed to find a homolog of ANG in the *Bombyx* genome and the enzyme that cleaves tRNAs in BmN4 cells is unidentified, major cleavage sites within the anticodon-loop were located between cytidine and uridine or guanosine and uridine (Figure 3E). This is similar to the ANG-cleavage patterns for the production of tRNA halves in human cancer cells (10).

**BmThg11-mediated uridine addition at –1 np of tRNA\(_{HisGUG}\) is required for the expression of td-piR\(_{HisGUG}\)**

Among all species of tRNAs, tRNA\(_{HisGUG}\) is unique in that it contains an additional 5\'-terminal nucleotide at np –1. Although the presence of guanosine at np –1 (G\(_{-1}\)) has been widely known to be conserved across phyla (2), our recent study revealed the existence of other three –1 nucleotides (U\(_{-1}\) >> A\(_{-1}\) C\(_{-1}\)) in tRNA\(_{HisGUG}\), in addition to G\(_{-1}\), and its 5\'-half expressed in human BT-474 breast cancer cells (53). As observed in BT-474 cells, cP-RNA-seq data showed wide variations of 5\'-terminal nucleotides from 5\'-halfHisGUG in BmN4 cells. In addition to 5\'-halfHisGUG lacking a –1 nucleotide (G\(_{1}\)) or containing G\(_{-1}\), 5\'-halfHisGUG containing U\(_{-1}\) and A\(_{-1}\) also were substantially expressed (16.6% and 10.7%, respectively) (Figure 3A, 3B). Therefore, the expression of tRNA\(_{HisGUG}\) halves was inhibited by only deacylation treatment, but not by sodium periodate oxidation, followed by cP-elimination. The mature tRNA\(_{AspGUC}\), 3\'-terminal cP-containing 5\'-tRNA halves and td-piRNAs were analyzed enzymatically. (A) 5\'-terminal structure of tRNA halves expressed in BmN4 cells. (A) The 3\'-terminal structures of 5\'-tRNA halves and td-piRNAs derived from tRNA\(_{AspGUC}\) and tRNA\(_{HisGUG}\) were analyzed enzymatically. BmN4 total RNA was treated with CIP or T4 PNK (PNK). NT designates non-treated samples used as negative controls. The treated total RNA was subjected to 3\'-adapter ligation by T4 Rnl, and the ligation efficiency was estimated by quantifying adapter-ligated target RNAs (5\'-tRNA halves or piRNAs) using TagMan qRT-PCR. Ligated products in NT samples were set as 1, and relative amounts are indicated. Averages of three independent experiments with SD values are shown. (B) To analyze the 3\'-terminal structure of 3\'-tRNA halves, BmN4 total RNA was subjected to deacylation treatment and sodium periodate oxidation, followed by β-elimination. The mature tRNA\(_{AspGUC}\), 3\'-halfAspGUC, tRNA\(_{HisGUG}\), 3\'-halfHisGUG, and let-7 miRNA (control) in the treated total products were analyzed by Northern blots.

5\'-tRNA halves in BmN4 cells are derived from only specific tRNA species including tRNA\(_{AspGUC}\) and tRNA\(_{HisGUG}\)

The 3\'-terminal cP or amino acid of tRNA halves would inhibit the adapter ligation step included in standard RNA-seq methods, and therefore, the expression of tRNA halves cannot be captured by analyzing standard RNA-seq data. Instead, we utilized ‘cP-RNA-seq’ to identify expression profiles of 5\'-halves expressed in BmN4 cells because it is able to selectively amplify and sequence RNAs containing a 3\'-cP (10,49). Because selective amplification of cP-containing RNAs in this method is dependent on the periodate-mediated cleavage of other RNAs with a 3\'-OH end, the 3\'-terminal ribose 2\'-O-methylation of piRNAs (54–57) was expected to make piRNAs amplifiable by cP-RNA-seq despite the absence of a 3\'-cP (49). Indeed, as shown in Figure 3A, piRNAs were amplified by the procedure even without CIP and T4 PNK treatments as ~145-bp cDNA bands (considering adapters’ lengths, inserted RNAs were estimated to be ~27 nt). However, the full cP-RNA-seq procedures amplified ~153-bp cDNA bands (inserted RNAs: ~35 nt) that were much more abundant than piRNA bands in the same lane (Figure 3A). The dependency of the bands on T4 PNK treatment suggests that, as expected, the bands were derived from cP-containing 5\'-tRNA halves.

Figure 2. Terminal structure analyses of tRNA halves expressed in BmN4 cells. (A) The 3\'-terminal structures of 5\'-tRNA halves and td-piRNAs derived from tRNA\(_{AspGUC}\) and tRNA\(_{HisGUG}\) were analyzed enzymatically. BmN4 total RNA was treated with CIP or T4 PNK (PNK). NT designates non-treated samples used as negative controls. The treated total RNA was subjected to 3\'-adapter ligation by T4 Rnl, and the ligation efficiency was estimated by quantifying adapter-ligated target RNAs (5\'-tRNA halves or piRNAs) using TaqMan qRT-PCR. Ligated products in NT samples were set as 1, and relative amounts are indicated. Averages of three independent experiments with SD values are shown. (B) To analyze the 3\'-terminal structure of 3\'-tRNA halves, BmN4 total RNA was subjected to deacylation treatment and sodium periodate oxidation, followed by β-elimination. The mature tRNA\(_{AspGUC}\), 3\'-halfAspGUC, tRNA\(_{HisGUG}\), 3\'-halfHisGUG, and let-7 miRNA (control) in the treated total products were analyzed by Northern blots.
As 5′-halfHisGUG originates from mature tRNAHisGUG, a U−1 nucleotide should be present in mature tRNAHisGUG. The *Bombyx mori* genome contains 14 tRNAHisGUG genes that encode identical mature tRNAHisGUG sequences. Because all 14 genes have adenine at their −1 positions on the genome, the U−1 nucleotide should be added post-transcriptionally. tRNAHis guanylytransferase (Thg1) has been shown to post-transcriptionally add G−1 to tRNAHisGUG (58). We retrieved sequences of the *BmThg1* gene, a *Bombyx* homolog of the human THG1L, which is localized on *Bm* scaf13 of chromosome 4 (Supplementary Figure S3). Because Thg1 or Thg1-like protein from *Bacillus*, archaea, and yeast can attach not only G−1, but also U−1, to the tRNA in vitro (59,60), we hypothesized that the *BmThg1* protein is involved in the U−1 addition to tRNAHisGUG, which is required for the production of td-piRHisGUG. To examine this, we performed an RNAi knockdown of *BmThg1* expression, which was effective for decreasing *BmThg1* mRNA levels to ~12% compared with the control knockdown (Figure 4C). The *BmThg1* knockdown did not change the staining patterns of total RNA and the total piRNA fraction (Figure 4D). Strikingly, Northern blot using a large-size gel with a single nucleotide resolution revealed a lack of −1 nucleotides in mature tRNAHisGUG upon *BmThg1* depletion (Figure 4E). Moreover, the *BmThg1* knockdown caused a removal of the −1 nucleotide of 5′-halfHisGUG (Figure 4F). These results suggest that *BmThg1* is the enzyme that adds the −1 nucleotide to mature tRNAHisGUG in *Bm* cells, and that the anticodon cleavage of the tRNA occurs after the −1 nucleotide addition, so that the −1 nucleotide property can be inherited by its 5′-half. TaqMan qRT-PCR quantification revealed the specific reduction of td-piRHisGUG upon *BmThg1* depletion. All other examined piRNAs showed no quantitative changes (Figure 4G), which is consistent with the unchanged levels of total piRNAs shown in Figure 4D. The specific requirement of *BmThg1* for...
Figure 4. Analyses of tRNA^{HisGUG} and td-piR^{HisGUG} in BmThg1l-depleted BmN4 cells. (A) Pie chart showing the 5′-terminal variations of BmN4 5′-halfHisGUG identified by cP-RNA-seq. (B) Pie charts showing the 5′-terminal variations of BmN4 td-piR^{HisGUG} bound to Siwi and BmAgo3. (C) BmThg1l mRNA from BmN4 cells treated with dsRNAs targeting Renilla luciferase (Rluc, negative control) or BmThg1l was quantified by qRT-PCR. Each dataset represents the average of three independent experiments with bars showing the SD. (D) Total RNA from Rluc- or BmThg1l-depleted cells was subjected to denaturing PAGE and stained by SYBR Gold. Long exposure enabled clear observation of the piRNA bands. (E, F) Total RNA from Rluc- or BmThg1l-depleted cells was subjected to Northern blot targeting the 5′-part of tRNA^{HisGUG} using a large-size gel with 1 nt resolution for mature tRNA (E) or a standard-size gel for its 5′-half (F). Because the 5′-part of the tRNA is targeted, both mature tRNA^{HisGUG} and 5′-halfHisGUG were detected. td-piR^{HisGUG} was not detected due to a lack of sensitivity. For both mature tRNA and 5′-half, a band with slightly smaller size appeared upon BmThg1l-depletion, suggesting the role of BmThg1l in the –1 nucleotide addition to tRNA^{HisGUG}. Bands shown with an asterisk might be non-specific as they seemed unaffected by the BmThg1l depletion. (G) The indicated piRNAs and let-7 miRNA in the Rluc- or BmThg1l-depleted cells were quantified by TaqMan qRT-PCR (Supplementary Figure S1) or qRT-PCR using a stem-loop primer. The amounts in Rluc-depleted cells were set as 1, and relative amounts are indicated. Averages of three independent experiments with SD values are shown.
The expression of 5′-halves is linked to the expression of td-piRNAs

Both tRNA species identified as major sources for td-piRNAs, tRNAAspGUC and tRNAHisGUG (Figure 1), also have been identified as major sources for 5′-tRNA halves (Figure 3). tRNAGluUUC and tRNAHisGUG have also been detected as a source for both td-piRNAs and 5′-tRNA halves. This link has prompted us to hypothesize that 5′-halves, not mature tRNAs, could be direct intermediates for the production of td-piRNAs. A high proportion of piRNAs contain a uridine at their 5′-end, and the presence of 5′-terminal uridine is a prerequisite for piRNA precursors to be loaded onto Piwi proteins in BmN4 cells (47). If mature tRNAs are direct substrates for piRNA precursors to be loaded onto Piwi proteins and thereby make them inappropriate piRNA precursors.

To examine the involvement of 5′-halves in the biogenesis of td-piRNAs, we focused on NSun2, an RNA methyltransferase that methylates tRNAs to generate a 5′-methylcytosine (m5C) modification (61,62). The NSun2-produced m5C modification protects the modified tRNAs from the anticodon cleavage and, therefore, prevents the generation of tRNA halves (14,63). In cells lacking NSun2 activity, the loss of the m5C modification made tRNAs more susceptible to anticodon cleavage and caused an accumulation of tRNA halves (14). These studies have designated NSun2 as a regulator factor for tdRNA half expression. From the Bombyx genome, we retrieved sequences of the BmNSun2 gene, a Bombyx homolog of the human NSUN2, which is localized on Bm scaf37 of chromosome 20 (Supplementary Figure S4). RNAi knockdown of BmNSun2, which was effective in decreasing BmNSun2 mRNA levels to ~20% compared with the control reaction (Figure 5A), did not alter the expression patterns of total RNAs (Figure 5B) or control 5S rRNA (Figure 5C). In contrast, as expected, Northern blots showed the increased levels of both 5′-halfAspGUC and 5′-halfHisGUG upon BmNSun2 depletion, whereas the levels of corresponding mature tRNAs showed no alteration (Figure 5D). Strikingly, along with the increase in the 5′-halves, expression levels of td-piRAspGUC also increased upon BmNSun2 depletion (Figure 5D), although total piRNA abundance seemed not to have been altered (Figure 5B). Similarly, BmNSun2 depletion increased the levels of 5′-halfGluUUC and td-piRAspGUC (Supplementary Figure S5C).

Because our northern blot lacked the sensitivity to detect td-piRAspGUC as a clear band (Figure 5D), we established a more sensitive TaqMan qRT-PCR method (Supplementary Figure S1) that can selectively and specifically quantify 5′-halfAspGUC (np 1–34), td-piRAspGUC (np 1–28), 5′-halfHisGUG (np 1–34) and td-piRHisGUG (np 1–26). Total RNA was first subjected to sodium periodate oxidation to disrupt the 3′-OH ends of RNAs. For quantification of the piRNAs, subsequently, a 3′-adapter was ligated to the 3′-ends of the piRNAs, and quantification of the ligation products was then achieved by TaqMan qRT-PCR. For quantification of the 5′-halves, the periodate-treated RNA was further treated with T4 PNK to remove a 3′-cP, and then followed by a 3′-adapter ligation and TaqMan qRT-PCR quantification. These methods revealed that the expression levels of both 5′-halfAspGUC and 5′-halfHisGUG as well as their corresponding td-piRNAs, td-piRAspGUC and td-piRHisGUG, were all enhanced upon BmNSun2 knockdown (Figure 5E). Taken together, these data suggest that, in BmNSun2-deleted cells, an increase in the expression levels of 5′-halves enhanced the expression levels of corresponding td-piRNAs without quantitative change in mature tRNAs, indicating that the 5′-halves, not the mature tRNAs, are the direct precursors for td-piRNAs.

**DISCUSSION**

The number of reports characterizing the expression and function of tRNA-derived ncRNAs has been growing, which enforces the conceptual consensus that tRNAs are utilized to produce functional ncRNAs. A wide variety of specific tRFs are differentially expressed in different cells, tissues, and organisms; however, the molecular mechanisms governing the specific expression patterns of tRFs have not been clarified yet. Although the functional significance of tRFs has been increasingly apparent, the lack of information on their biogenesis mechanism limits our understanding of the necessity and inevitability of specific tRF expression profiles, as well as the reasons why cells utilize tRNAs for ncRNA production.

Here we report the biogenesis mechanism for td-piRNAs in Bombyx BmN4 cells, which could explain why only specific tRF species are expressed as piRNAs in the cells. In the current model for canonical piRNA biogenesis pathways, single-stranded RNAs are transcribed from defined genomic regions called piRNA clusters (37,64), and are likely fragmented into shorter precursor piRNAs by the involvement of Zucchini endonuclease and other unknown proteins (65–67). In BmN4 cells, precursor RNAs containing a 5′-terminal uridine are then selectively loaded onto Piwi proteins, followed by a PNLDC1-catalyzed 3′-to-5′-exonucleolytic trimming, that is supported by BmPapi, for the 3′-end formation of mature piRNAs (44,47,48). Our analyses on Siwi- and BmAgo3-bound piRNAs identified the 5′-tRFs derived from cyto tRNAAspGUC and tRNAHisGUG as major species of td-piRNAs (Figure 1).
Our cP-RNA-seq identified tRNA\textsuperscript{AspGUC} and tRNA\textsuperscript{HisGUG} as major sources for 5′-tRNA halves as well (Figure 3). tRNA\textsuperscript{GluUUC} and/or tRNA\textsuperscript{GluUC} were also detected as substrates for both td-piRNAs and 5′-tRNA halves. We assumed the common appearance of these tRNAs as substrate for both td-piRNAs and 5′-tRNA halves was not just a coincidence but fact suggesting a direct link between the expression of td-piRNAs and 5′-tRNA halves. Indeed, the increase of 5′-tRNA halves upon the knockdown of BmNSun2 clearly enhanced td-piRNA expression (Figure 5). These data, together with unchanged levels of mature tRNAs in BmNSun2-depleted cells, allow us to propose a biogenesis mechanism for td-piRNAs in which 5′-tRNA halves, rather than mature tRNAs, are the direct precursors for td-piRNAs (Figure 6). In our model, mature tRNAs are first cleaved at the anticodon-loop to produce tRNA halves. Among the generated 5′-tRNA halves, only those containing a 5′-terminal uridine are loaded onto Piwi proteins to be processed into td-piRNAs. Consequently, our model could provide an explanation for the expression of only a few specific td-piRNA species.
The molecular mechanism underlying the anticodon-loop cleavage of only specific tRNA species in BmN4 cells remains unknown. In mammalian cells, ANG cleaves the anticodon-loops of mature tRNAs to produce tRNA halves, which is triggered by stresses and sex hormone signaling pathways (9,10,68). Although we could not find the Bombyx homolog of human ANG, the presence of a 3′-cP in 5′-tRNA halves (Figure 2) and major anticodon-loop cleavage sites between cytidine and uridine or guanosine and uridine (Figure 3) resembles the characteristics of ANG-generated 5′-tRNA halves in human cancer cells (10). Therefore, an endonuclease similar to ANG could be involved in the production of tRNA halves in BmN4 cells.

In contrast to previous reports describing the 5′-terminal G−1 as a major presence in tRNAHisGUG, the identified 5′-terminal variations of 5′-halfHisGUG revealed the substantial presence of the U−1 residue (Figure 4), which is consistent with our recent study on 5′-halfHisGUG in human cancer cells (53). The major presence of the U−1 residue in td-piRHisGUG (Figure 4) should be attributable to their selective loading onto Piwi proteins. The expression of td-piRHisGUG is clearly dependent on BmThg1l (Figure 4), suggesting that BmThg1l contributes to the activity of adding U−1, as well as G−1, to tRNAHisGUG, and that the BmThg1l protein is a significant regulator for the expression of tRFs derived from tRNAHisGUG.

Why are piRNAs not produced from mature tRNAs, but from tRNA halves? Since an amino acid was attached to the 3′-end of the 3′-tRNA half (Figure 2), tRNA halves should be produced by an anticodon-loop cleavage of mature aminoacylated tRNAs. Aminoacylated tRNAs are tightly bound by an elongation factor for translation. Therefore, their structure might be too rigid for piRNA biogenesis factors and/or Piwi proteins to access for piRNA production. The anticodon-loop could be among the most readily accessible regions for enzymes, which might be the reason that mature tRNAs are first cleaved at anticodon-loop, and then resultant tRNA halves, released from an elongation factor, become direct precursors for piRNAs. If this is the case, it might be possible that tRNA halves could also be direct precursors for many other tRFs, such as tRNA-derived miRNAs bound by Ago proteins. Because the expression of tRNA halves is variable in different cells and tissues, and is further regulated by tRNA modification states, various stressors, and hormones (9,10,14), the uniquely regulated biogenesis mechanism of tRNA halves may consequently provide the opportunity for cells to generate specific classes of tRNA-derived small regulatory RNAs whose species and abundance then also would be uniquely controlled. It will be intriguing to examine further the role of tRNA halves as direct precursors in the production of various shorter tRFs. Such attempts will advance our knowledge on the significance and functional meaning of differential expression profiles of tRNA-derived ncRNAs.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS

We are grateful to Dr Megumi Shigematsu for helpful discussions.

Authors’ contributions: S.H. and Y.K. conceived the project and designed experiments. S.H., T.K. and K.M. performed experiments. S.H., P.L., K.M. and I.R. analyzed sequence data and all authors discussed the results. S.H. and Y.K. wrote the paper with input from other authors.

FUNDING

National Institutes of Health [GM106047 to Y.K.]; W.M. Keck Foundation grant (to I.R.); Institutional funds (to Y.K. and I.R.); JSPS Postdoctoral Fellowships for Research Abroad (to S.H.). Funding for open access charge: National Institutes of Health [GM106047 to Y.K.].

Conflict of interest statement. None declared.

REFERENCES


